News | October 29, 2021
Zydus Wellness PAT at Rs. 21.47 cr. in Q2FY22
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Cipla has reported consolidated financial results for the period ended September 30, 2021
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Support from DFC will help produce one billion vaccine doses by the end of 2022
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Subscribe To Our Newsletter & Stay Updated
